PP03 Presentation Time: 8:38 AM
Clinical implementation of MRI-only treatment planning (MRTP) for HDR brachytherapy can eliminate the need for CT from the current CT/MRI-based treatment planning process. Removal of CT from the workflow can potentially reduce the error and time associated with image registration and improve the overall planning process. An optimized ‘Pointwise Encoding Time Reduction with Radial Acquisition (PETRA)’ MR sequence has been shown to allow an accurate reconstruction of interstitial catheters, without relying on CT. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Casey Y. Lee, Evangelia Kaza, Thomas C. Harris, Desmond A. O'Farrell, Martin T. King, Michael A. Dyer, Idalid Franco, Robert A. Cormack, Ivan Buzurovic Source Type: research
PP04 Presentation Time: 8:47 AM
Prospectively measure change in vaginal length after definitive Chemoradiation (C-EBRT) with Intracavitary Brachytherapy (ICBT) for locally advanced cervix cancer (LACC) and correlate with vaginal dose (VD) (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Amir Owrangi, Astrid Medrano, Yin Gao, Brian Hrycushko, Paul Medin, Chika Nwachukwu, Xun Jia, Kevin Albuquerque Source Type: research
PP05 Presentation Time: 8:56 AM
A range of standard dose-fractionation schedules for high dose rate (HDR) vaginal cuff brachytherapy (VBT) following hysterectomy is recommended by published guidelines including 3, 4, 5 and 6 fraction (Fx) regimens with prescription varying from the surface to a depth of 5 mm. Currently, there are no dose constraints for organs at risk (OARs) in VBT. Given the presumed relatively low OAR doses, these OAR doses are simply recorded with minimal to no dosimetric adjustment during treatment planning. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Niki Tselepidakis, Tatiana Bejarano, Ruyun Jin, Bethany Horton, Wendy Zheng, Timothy Showalter, Einsley-Marie Janowski, Kara Romano Source Type: research
PP06 Presentation Time: 9:05 AM
Addressing religion and spirituality (R/S) in the patient care setting can improve coping with illness, decrease rates of depression, increase compliance, improve patient hope, quality of life, and the patient-provider relationship. Given that gynecologic brachytherapy treatments often lead to increased stress and fear among patients, we assessed the incorporation of R/S in order to improve patient-physician communication. The FICA spirituality history taking tool outlines four domains for patient spiritual assessment: Faith or belief, Importance of spirituality on an individual's life and health care decision making, indi...
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Lauren Michelle Jacobs, Jason Gurewitz, Stella Lymberis Source Type: research
Thursday, June 22, 20239:20 AM - 10:20 AMPP01 Presentation Time: 9:20 AM
The recently reported randomized Phase III trial comparing health related quality of life (HRQOL) after combined external beam radiation therapy (EBRT) and either HDR or LDR brachytherapy (BT) found a significant decline in the EPIC Bowel domain HRQOL score at 24- 48 months after treatment in the LDR arm of the trial. As all patients in the trial received the same EBRT dose, and HDR rectal dose was strictly controlled to be (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Felipe Castro Canovas, Juanita Crook, Gregory Arbour, Cynthia Araujo, Deidre Batchelar, Nikitha Moideen, Michelle Hilts, Ross Halperin, David Kim, David Petrik, Jim Rose, Francois Bachand Tags: Scientific Session: Prostate Proffered Papers I Source Type: research
PP02 Presentation Time: 9:29 AM
Rectal toxicity remains a dose-limiting side effect of definitive prostate radiation. There are limited long-term data on patient-reported rectal toxicity outcomes following Pd-103 LDR prostate brachytherapy, as well as some recent data suggesting high rates of long-term toxicity from LDR brachytherapy overall. We aim to report incidence and predictors of late patient-reported rectal quality of life outcomes after Pd-103 brachytherapy. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Keara English, Tanmay Singh, Todd McNutt, Emerson Lee, Gayane Yenokyan, Hee Jin Bae, Theodore DeWeese, Daniel Song Source Type: research
PP03 Presentation Time: 9:38 AM
We present data from a cohort of our patients treated with PB using Cs131 to compare our results with the 5-year data from the recently published SBRT trial from NRG Oncology RTOG 0938. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Mohammed Adel Shehata Mohammed, Ronald Benoit, Sushil Beriwal, Ryan Smith Source Type: research
PP04 Presentation Time: 9:47 AM
It is currently known that the group of intermediate risk of prostate cancer [PC] is heterogeneous and according to the NCCN classification includes 2 subgroups - favorable and unfavorable intermediate risk [UIR]. The optimal scope of therapy was not defined for the UIR subgroup. In particular, there are no unambiguous recommendations about the total radiotherapy dose, as well as on the need and volume of hormone therapy [HT].Purpose: A comparative analysis of the efficacy of external beam radiation therapy [EBRT] and brachytherapy [BT] with or without androgen deprivation therapy [ADT] in UIR PC patients. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Vitaly A. Biryukov, Kseniia S. Makarova, Yulia V. Gumenetskaya, Tatyana A. Rodina, Anastasia B. Galitsyna, Elizaveta O. Shchukina, Oleg B. Karyakin, Sergey A. Ivanov, Andrey D. Kaprin Source Type: research
PP05 Presentation Time: 9:56 AM
To assess the performance of multiparametric (mp) MRI in identification of intraprostatic tumor deposits in patients previously treated with local radiation therapy (RT) using a systematic and targeted MR-gided transperineal prostate biopsy technique. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Tyler E. Gutschenritter, Anthony Pham, Homayon Parsai, Merriah Montague, Sarah Reith, Justin Bell, Rosanna Mangibin, Joe Bradlo, Richard Alex Hsi Source Type: research
PP06 Presentation Time: 10:05 AM
The efficacy of low dose rate (LDR) and high dose rate (HDR) brachytherapy for prostate cancer have been well established. Fewer studies directly compare short-term perioperative complications between these modalities, and these often have small sample sizes and heterogeneous settings including brachytherapy boost after external beam radiotherapy (EBRT). The purpose of this study is to investigate the perioperative and subacute postoperative complications in patients undergoing exclusively LDR or HDR monotherapy at a single institution with a high volume brachytherapy program. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Peter Lee, Karen Ruth, Douglas Lee, Mark Hallman, David Chen, Jessica Karen Wong, Andres Correa, Iavor Veltchev, Teh Lin, Xiaoming Chen, Joseph Panetta, Alexander Kutikov, Eric Horwitz Source Type: research
Thursday, June 22, 20233:30 PM - 4:30 PMPP01 Presentation Time: 3:30 PM
The goal of this work was to investigate the dosimetric impact of two different techniques to determine the needle depth commonly used in intraoperative ultrasound-guided prostate high dose rate (HDR) brachytherapy. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Abigail E. Besemer, Sarah Wisnoskie, Jeffrey Wong Tags: Scientific Session: Physics Proffered Papers I Source Type: research
PP02 Presentation Time: 3:39 PM
The AAPM& GEC-ESTRO Task Group No. 192 Report was published in 2014. Since then, improvements in robotic brachytherapy technology have been realized and a large number of new robotic systems were developed. In addition, progress has been made on translating some of these devices from laboratory to clinical practice. In response to these advances, the AAPM Brachytherapy subcommittee and GEC-ESTRO BRAPHYQS subcommittee convened a joint task group (TG-342) charged with updating the TG-192 report and providing comprehensive guidelines for implementation of these robotic devices in the clinic. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Tarun Podder, Adam Cunha, Ivan Buzurovic, Rochdi Merzouki, Marinus Moerland, Mark Rivard, Alexander Schlaefer, Daniel Song, Bryan Traughber, Kaiguo Yan, Christian Langmack, Yan Yu Source Type: research
PP03 Presentation Time: 3:48 PM
The precise localization of radioactive sources within an applicator is of paramount importance for the correct delivery of a Brachytherapy treatment. Conventionally Gafchromic, radiochromic films or a monitoring camera are used to visualize a radioactive seed location in catheter in open air during Daily QA. During HDR brachytherapy patient treatment the seed location is not measured but inferred from the catheter length specified in the TPS. We developed a novel seed location sensing method for real-time, ex-/in-vivo monitoring of the source location within a catheter. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Davide Brivio, Matt Gagne, Mandar Bhagwat, Ivan Buzurovic, Erno Sajo, Piotr Zygmanski Source Type: research
PP04 Presentation Time: 3:57 PM
Recent progresses in high-dose-rate (HDR) cervical cancer brachytherapy showed that complex interstitial (IS) and intracavity applicators, such as the Venezia applicator (Elekta, Veenendaal, The Netherlands), can improve the HR-CTV coverage while adequately protecting organs at risk (OARs). Although the Venezia applicator offers more degrees of freedom for catheter selection, efficient catheter and dose optimization algorithms are still lacking; it is difficult for practitioners to determine the optimal catheter configuration to achieve Pareto-optimal treatment plans. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: C édric Bélanger, Marie-Claude Lavallée, Sylviane Aubin, Luc Beaulieu Source Type: research
PP05 Presentation Time: 4:06 PM
Breast conserving surgery plus accelerated partial breast irradiation is increasingly popular for early-stage breast cancer patients with promising clinical outcomes. However, the identification of the seroma cavity on CT can be challenging, leading to inaccuracy and inconsistency in seroma contouring. For brachytherapy techniques this presents additional challenges. Three-dimensional ultrasound (3DUS) technology will significantly improve target visualization and implant accuracy. In this work, we introduce a robotic 3DUS system with a spatial tracking arm that has great potential for improved visual guidance in breast br...
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Claire Zhang, Shuwei Xing, Lori Gardi, Aaron Fenster, Juanita Crook, Deidre Batchelar, Michelle Hilts Source Type: research
